ESMO 2020 VL

Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Can...

Details
Medical Oncologist, Ben Tran, MBBS, FRACP, joins Alicia Morgans, MD, MPH, Oliver Sartor, MD, and Neal Shore, MD, FACS to speak about the first in-human study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific t-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) designed to understand the effects of BiTE AMG 160 and prostate cancer cells....

Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff

Details
AMG 160 is a half-life extended (HLE) BiTE® molecule designed to engage the patient’s own T cells with PSMA on prostate cancer cells, activating the cytotoxic potential of T cells to eliminate cancer. In this conversation with Alicia Morgans, MD, MPH, Medical Oncologist, Researcher, and co-investigator on the first in human, interim results of a phase 1 study of AMG 160, Tanya Dorff, MD from the C...

A New Class of Immunotherapeutic Molecules for Metastatic Prostate Cancer in Development - Karim Fizazi

Details
There is an urgency to develop therapies to treat prostate cancers resistant to chemohormonal and radiation therapies. Unfortunately, immune therapies have offered limited efficacy in patients with metastatic castration-resistant prostate cancer. At the 2020 European Society for Medical Oncology (ESMO) Annual Meeting, interim results from a phase 1 study of AMG 160, a targeted half-life extended,...

IPATential150: Phase III Study of Ipatasertib plus Abiraterone vs Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer - Cora Sternberg

Details
PTEN-loss is relatively common in advanced prostate cancer and is associated with worse prognosis as well as reduced benefit from androgen-axis targeting agents. Ipatasertib is a novel oral anti-cancer agent, under investigation in prostate and breast cancers. Orally administered, it is designed to target three isoforms of AKT (protein kinase B), in order to block the PI3 Kinase/AKT signaling path...

The Final Results of KEYNOTE-361 - Ajjai Alva

Details
Immune checkpoint blockade therapy by blocking PD-1/PD-L1 axis signaling is approved in advanced urothelial cancers in a few settings: (1) first-line therapy for platinum-ineligible patients, (2) first-line therapy in cisplatin-ineligible patients with high PD-L1 expression, (3) maintenance therapy for patients who do not progress with first-line chemotherapy, and (4) as subsequent therapy for pat...

Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde

Details
Guru Sonpavde joins Alicia Morgans, MD, MPH in a discussion on the treatment landscape of muscle-invasive bladder cancer and several trials that could lead to changes in treatment patterns across the bladder cancer disease spectrum. They review data recently presented at the 2020 European Society for Medical Oncology Virtual Congress, (ESMO) including sacituzumab govitecan in Cohort 3 of the TROPH...

Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain

Details
Reconsidering back-to-back AR-directed therapies: An interview with Maha Hussain, co-principal investigator of the PROfound study. Precision medicine and targeted therapy are possible in prostate cancer. Unmet needs have included more focused treatment and novel modes of action to counter resistance to hormonal and cytotoxic therapies. The PROfound sstudy of the PARP inhibitor olaparib in heavily...

Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar

Details
The identification of predictive biomarkers for immunotherapy response is an area of intense research interest. In this conversation with Alicia Morgans, MD, MPH, Srikala Sridhar MD, MSc, FRCPC highlights her presentation from the European Society for Medical Oncology (ESMO) 2020 virtual meeting. At this meeting, Dr. Sridhar presented an assessment of potential biomarkers for response within the J...

Outcomes Related to Cancer Treatments in Patients with COVID-19 from the CCC19 Registry Analysis- Ali Khaki, Jeremy Warner & Petros Grivas

Details
The COVID-19 and Cancer Consortium (CCC19) is a consortium of over 120 cancer centers and organizations coming together to collect data about patients with cancer who have been diagnosed with COVID-19. Ali Khaki, MD, Jeremy Warner, MD, MS, FAMIA, FASCO, and Petros Grivas, MD, Ph.D., join Alicia Morgans, MD, to discuss how the CCC19 consortium has evolved since first being established earlier this...

Abiraterone Acetate plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic (M1) Patients in the STAMPEDE Randomized Trial - Nicholas James

Details
The list of approved and guideline-recommended agents in metastatic hormone-sensitive prostate cancer (mHSPC) has seen significant changes in recent years. At the European Society of Medical Oncology (ESMO) 2020 Virtual Meeting, Dr. Nicholas James presented updated, long-term results of the STAMPEDE Arm G comparison examining abiraterone acetate plus prednisolone in addition to androgen deprivatio...